The results demonstrated that patients with HR+, HER2-metastasizing, and endocrine-therapy-resistant breast cancer had a moderate efficacy and a good safety profile when given pilaralisib or voxtalisib in conjunction with letrozole [88]. Here, ERBB2 is linked to breast cancer.